Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Combined Company to Trade on Nasdaq Under Ticker “IMA”

Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock

BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena’s stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals (“Inmagene”).

Read more at globenewswire.com